LHLeilei Han

Leilei Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leilei Han has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Jie Feng

    Department of Cardiology The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University Nanchang China

    2 shared publications
  • Yanqing Wu

    Department of Cardiology, The Second Affiliated Hospital, Jiangxi medical College, Nanchang University, Nanchang, China

    2 shared publications
  • Feng Xie

    Department of Cardiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China, ncu.edu.cn

    1 shared publication
  • Kai Li

    Department of Cardiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, China, ncu.edu.cn

    1 shared publication
  • Kai Li

    Department of Cardiology The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University Nanchang China

    1 shared publication
  • Meng Li

    Department of Cardiology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330006, P.R. China

    1 shared publication

Latest Publications

  • Open Access

    Targeting Pulmonary Hypertension: Elucidating Sophocarpine’s Protective Role via Preclinical Models

    by Feng Xie, Jie Feng, Kai Li, Yi Chen, Leilei Han, Yanqing Wu

    Background: Pulmonary hypertension (PH) is a serious disease that manifests itself as elevated pressure within the pulmonary arteries. The onset of PH is usually insidious, and if left untreated, it may lead to heart failure and even life‐threatening conditions. Recent studies have shown that sophocarpine (SOP) has significant effects on antioxidant, anti‐inflammatory, antifibrotic, and hemodynamic improvement, and it may become an emerging drug for the treatment of PH. However, the specific mechanism of action of SOP still requires further experimental validation. Methods: We established in vivo and in vitro models of PH and treated them with varying concentrations of SOP. To visualize the changes in rats and cells, we used scratch assay, flow cytometry, Western blotting, pulmonary artery pressure measurement, biochemical analysis, enzyme‐linked immunosorbent assay (ELISA), ultrasound scanning, hematoxylin and eosin (HE) staining, and Masson’s trichrome staining. Results: Our results showed that SOP significantly alleviated the inflammatory response and apoptosis induced by PH, reduced pulmonary artery pressure, and restored the balance of pulmonary artery remodeling. These effects were found to be effective in alleviating PH. Conclusion: Our study provides clear evidence that SOP has a significant protective effect in the PH model and is expected to be a promising therapeutic agent for PH.

  • Open Access

    Systematic Review of Interleukin‐35 in Endothelial Dysfunction: A New Target for Therapeutic Intervention

    by Kai Li, Jie Feng, Meng Li, Leilei Han, Yanqing Wu

    Endothelial dysfunction is a significant factor in the pathogenesis of various diseases. In pathological states, endothelial cells (ECs) undergo activation, resulting in dysfunction characterized by the stimulation of inflammatory responses, oxidative stress, cell proliferation, blood coagulation, and vascular adhesions. Interleukin‐35 (IL‐35), a novel member of the IL‐12 family, is primarily secreted by regulatory T cells (Tregs) and regulatory B cells (Bregs). The role of IL‐35 in immunomodulation, antioxidative stress, resistance to apoptosis, control of EC activation, adhesion, and angiogenesis in ECs remains incompletely understood, as the specific mechanisms of IL‐35 action and its regulation have yet to be fully elucidated. Therefore, this systematic review aims to comprehensively investigate the impact of IL‐35 on ECs and their physiological roles in a range of conditions, including cardiovascular diseases, tumors, sepsis, and rheumatoid arthritis (RA), with the objective of elucidating the potential of IL‐35 as a therapeutic target for these ailments.